natgillin/translations-raw huggingface dataset:
The discharge device 1 comprises a canister, reservoir or container 3 for pressurized liquid 4 . 
Naprava za pražnjenje 1 obuhvaća spremnik, rezervoar ili posudu 3 za stlačenu tekućinu 4.
Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group. 
Konkretni primjeri reakcija aromatske supstitucije uključuju uvođenje nitro skupine koristeći koncentriranu nitratnu kiselinu, uvođenje acilne skupine koristeći, na primjer, acil halid ili Lewis-ovu kiselinu (poput aluminij- triklorida) pod Friedl-Crafts uvjetima, i uvođenje halogeno skupine.
Pleasure boat according to claim 3, wherein said electrical power supply means comprise an electric generator connected to said propulsion means of said boat, the mechanical energy developed by said propulsion means being converted into electrical energy for said electrical power supply. 
Brod za zabavu (1;1) prema bilo kojem od zahtjeva 3 do 5, naznačen time da navedena sredstva električnog napajanja sadrže električni generator spojen na navedeno sredstvo za pogon navedenog broda, mehanička energija razvijena od strane navedenih pogonskih sredstava pretvara se u električnu energiju za navedeno električno napajanje.
a replacement at the endogenous mouse k immunoglobulin light chain variable region locus of endogenous mouse k immunoglobulin light chain variable region gene segments with a single human Vk1-39/Jk gene segment or a single human Vk3-20/Jk gene segment, wherein the human gene segment is operably linked to an endogenous mouse k constant gene and wherein the cell lacks an endogenous mouse k immunoglobulin light chain variable region locus that is capable of rearranging and forming a gene that encodes a mouse k variable region; and, 
zamjenu genskog segmenta varijabilne regije lakog lanca endogenog mišjeg k imunoglobulina na lokusu varijabilne regije lakog lanca endogenog mišjeg k imunoglobulina jednostrukim humanim genskim segmentom Vk- 20/1k, pri čemu je humani genski segment operativno povezan na endogeni mišji gen konstante k i pri čemu stanici nedostaje lokus varijabilne regije lakog lanca endogenog mišjeg k imunoglobulina koji je sposoban preurediti i formirati gen koji kodira mišju varijabilnu regiju k i
contacting a biological sample of the subject with at least one anti-human p53 antibody according to any of claims 1 to 2 under conditions suitable for the formation of an immunocomplex between the human p53 protein and the at least one antibody; and detecting the formation of an immunocomplex between the human p53 protein and the at least one antibody, the formation of the immunocomplex being indicative of predisposition to develop Alzheimer's disease. 
(1) < kontaktiranje biološkog uzorka subjekta s barem jednim anti-humanim p53 antitijelom prema bilo kojem od zahtjeva 1 do 2 pod uvjetima povoljnim za stvaranje imunokompleksa između humanog p53 proteina i barem jednog antitijela; 1 (ii) otkrivanje stvaranja imunokompleksa između humanog p53 protema i barem jednog antitijela, gdje je stvaranje imunokompleksa indikativno za predispoziciju razvijanja Alzheimerove bolesti.
The apparatus of claim 1 wherein the pump is reversible. 
Sustav prema zahtjevu 26, naznačen time što je peristaltička pumpa reverzibilna.
a Notch agonist, optionally DSL peptide; nicotinamide; 
pri čemu navedeni kultivirani medij dodatno sadrži Notch agonist.
In some embodiments, compounds of the present invention cause essentially no measurable flushing in an individual compared to an essentially equally effective dose of niacin. 
U nekim oblicima, spojevi prikazanog izuma uzrokuju gotovo ne mjerljivo crvenilo kod pojedinca u usporedbi s esencijalno isto učinkovitom dozom niacina.
The method according to claim 1 in which an anticoagulant agent is additionally present. The method according to claim 1 wherein the anticoagulant agent is heparin, dicoumarol, acenocoumarol, enoxaparine or pentosan polysulfate. 
Upotreba prema bilo kojem zahtjevu 18 do 26, naznačena time, da farmaceutski sastav nadalje sadrži antikoagulantno sredstvo, ponajprije heparin, dikumarol, acenokumarol, enoksaparin ili pentosan polisulfat.
Use according to any one of the preceding claims, characterised in that following the addition of said 2-aminoethanol, the suspension conductivity change in µS/cm/pH unit is maintained at a value within 10 %, preferably within 6 %, and more preferably within 3 %, of the suspension conductivity value prior to 2-aminoethanol addition. 
Uporaba prema bilo kojem od prethodnih zahtjeva, naznačena time što se nakon dodavanja 2-aminoetanola promjena provodljivosti suspenzije u uS/ecm/pH jedinica održava pri vrijednosti unutar 10 %, poželjno unutar 6 %, i poželjnije unutar 3 %, vrijednosti provodljivosti suspenzije prije dodavanja 2-aminoetanola.
dexamethasone (40 mg) administered on Days 15, 22, 29, and 36 (Cycle 1) and on Days 1, 8, 15, and 22 (Cycle 2 and subsequent cycles). 
(c) deksametazon (40 mg) administriran na Dane 15, 22, 29, 1 36 (Ciklus 1) i na Dane 1, 8, 15,122 (Ciklus 21 slijedeći ciklusi).
Specifically, the present invention is as described below. An RNAi molecule capable of suppressing expression of thymidylate synthase by RNAi action comprising a double-stranded RNA domain composed of a sense strand consisting of the nucleotide sequence represented by SEQ ID NO: 1, 3, or 5 hybridized to an antisense strand hybridizing under stringent conditions to the sense strand. 
RNKi-molekula, naznačena time, da je sposobna za obuzdavanje ekspresije sinteze timidilata pomoću RNKi- djelovanja, te koja obuhvaća RNK-domenu dvostruke konfiguracije sastavljenu od sens-konfiguracije koja se sastoji od nukleotidne sekvence predstavljene sa SEQ ID NO:1, hibridizirane na antisens-konfiguraciju koja se sastoji od nukleotidne sekvence predstavljene sa SEQ ID NO:2, pri čemu je sens-konfiguracija povezana na antisens-konfiguraciju preko područja povezivača.
The injector of claim 1, wherein the actuator is adapted to delay movement of the container needle from the storage state to the delivery state after an input is received. 
Ubrizgač prema bilo kojem od prethodnih zahtjeva, naznačen time, što je pokretač (456) prilagođen da odgodi kretanje igle spremnika (550, 702, 772) 1z pasivnog stanja u stanje za isporuku nakon primanja unosa.
a bispecific antibody (Q64-z7/J326-z107/L334-k), wherein the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 10, the second polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 6, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 30; a bispecific antibody (Q64-z7/J344-z107/L406-k), wherein the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 10, the second polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 7, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 33; 
6, a treći polipeptid 1 četvrti polipeptid su zajednički korišten L-lanac od SEQ ID NO: 30; bispecifično protutijelo, gdje prvi polipeptid je H-lanac koji se sastoji od aminokiselinske sekvence od SEQ ID NO: 10, drugi polipeptid je H-lanac koji se sastoji od aminokiselinske sekvence od SEQ ID NO: 7, a treći polipeptid 1 četvrti polipeptid su zajednički korišten L-lanac od SEQ ID NO: 33; bispecifično protutijelo, gdje prvi polipeptid je H-lanac koji se sastoji od aminokiselinske sekvence od SEQ ID NO: 11, drugi polipeptid je H-lanac koji se sastoji od aminokiselinske sekvence od SEQ ID NO:
The invert arm assembly of claim 19 wherein the second idler gear is disposed on one side of a line connecting an axis of rotation of the drive gear and an axis of rotation of the driven gear, and the other idler gear is on the other side of the line so that in one direction of rotation of the drive gear, the other idler gear transmits the rotational force to the driven gear, and in the other direction of rotation of the drive gear the second idler gear transmits the rotational force to the driven gear. 
Sklop invertirajuće ruke iz zahtjeva 18 naznačen time da je drugi potporni zupčanik (136b) smješten na jednoj strani linije koja spaja os zakretanja pogonskog zupčanika i os zakretanja pogonjenog zupčanika, a prvi potporni zupčanik (136a) je smješten na drugoj strani te linije, tako da u jednom smjeru vrtnje pogonskog zupčanika prvi potporni zupčanik prenosi zakretni moment na pogonjeni zupčanik, dok u drugom smjeru vrtnje pogonskog zupčanika zakretnu silu na pogonjeni zupčanik prenosi drugi potporni zupčanik
The method of claim 8, wherein the agent for treatment of diabetes is a biquanide, a sulfonylurea, a meglitinide, a glinide, a DPP-IV inhibitor, a glitazone, a GLP-1 agonist, an insulin, or an insulin analogue. 
(a) sredstvo za liječenje dijabetesa je metformin, sulfonilurea, glinid, DPP-IV-inhibitor, glitazon, inzulin ili analog inzulina;
For avoidance of any doubt, whenever one of the above embodiments refers to “peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ”, said X-ray powder diffraction diagram is obtained by using combined Cu Ka1 and Ka2 radiation, without Ka2 stripping; and it should be understood that the accuracy of the 2θ values as provided herein is in the range of +/−0.1-0.2°. 
1 24,5", dok se navedeni dijagram difrakcije praha X-zraka dobiva pomoću uporabe kombinirane radijacije Cu Kal i Cu Ka2, bez Koa2-strippinga; a preciznost za 20-vrijednosti leži u rasponu od 20 +/- 0,2".
The valve according to claim 7, wherein said control cylinder (57) is controlled by means of additional stimulation at said control valve (58) connected to a fluid receiving vessel (43). A hydraulic axial piston regulating valve, said valve comprising: 
Upotreba hidrauličkog aksijalno klipnog regulacijskog ventila prema zahtjevu 11, naznačena time da se rečenim upravljačkim cilindrom (57) upravlja pomoću dodatne simulacije na regulacijskom ventilu (58) koji je priključen na posudu za prihvat fluida (43).
The aqueous agrochemical suspension composition of any one of [1] to [3], wherein the inorganic thickener is at least one kind selected from the group consisting of magnesium aluminium silicate and montmorillonite. 
Vodena agrokemijska suspenzija u skladu sa bilo kojim od patentnih zahtjeva 1 do 3, gdje suspenzija je kompozicija i neorgansko sredstvo za zgušnjavanje je barem jedna vrsta odabrana iz grupe koja se sastoji od magnezij aluminij silikata i montmorilonita.
p is 0, 1 or 2; and salts thereof. 
p je 0, 1 ili 2; i njihove soli.
However, these packaging systems can not be designed like a book due to the characteristics of the metal material. 
Međutim, ovi sustavi pakiranja ne mogu biti smatrani kao knjige zbog karakteristika koje ima metalni materijal.
The antibody or antigen-binding fragment thereof of any one of claims 1 to 3, wherein the antibody or antigen-binding fragment thereof is conjugated to an agent selected from the group consisting of a therapeutic agent, a prodrug, a peptide, a protein, an enzyme, a virus, a lipid, a biological response modifier, a pharmaceutical agent, and polyethylene glycol (PEG). 
Protutijelo, ili njegov antigenski vežući fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačeno time što protutijelo, ili njegov antigenski vežući fragment, je konjugirano sa sredstvom kojeg se bira iz skupine koju čine terapijsko sredstvo, predlijek, peptid, protein, enzim, virus, lipid, biološki odgovor modifikator, farmaceutsko sredstvo, te polietilen-glikol (PEG).
Of particular interest are the following two A groups: 
Sljedeće A skupine su od posebnog interesa:
The method of claim 1 wherein the fiber structure of the feedstock is maintained during pretreatment. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se vlakanstu strukturu sirovine održava tijekom predobrade.
dissolving at least one preservative in one or more co-solvent(s), wherein at least one preservative is selected from a group comprising: m-cresol, chlorocresol, methylparaben, ethylparaben, propylparaben, or butylparaben, 
otopi najmanje jedan prezervativ u jednom ili više dodatnih otapala, gdje se najmanje jedan prezervativ bira iz skupine koja se sastoji od:
with a compound of general formula (V) 
(Iv) sa spojem opće formule (V)
oxidizing the compound of Formula XLVI to give a compound of Formula XLVII; 
Formula XLVII reakciju spoja Formule XLVII sa spojem Formule XIII, hal-Q
The method of claim 1, wherein in step b) the period is 5 to 50 minutes, 6 to 40 minutes, 7 to 30 minutes or 8 to 20 minutes. The method of claim 1, wherein in step b) the period is 10 minutes to 4 hours, 20 minutes to 3 hours, 30 minutes to 2 hours, 40 to 90 minutes, or 50 to 70 minutes. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je u koraku b) period 1 minute do 4 sata, 2 minute do 3 sata, 3 minute do 2 sata, 4 do 60 minuta, 5 do 50 minuta, 6 do 40 minuta, 7 do 30 minuta ili 8 do 20 minuta.
The use according to any one of claims 1-9, wherein the anti-CS1 1 antibody is administered once every 10 days. 
Uporaba prema zahtjevu 9, naznačen time da se bortezomib daje na dane 1, 4, 8 i 11, nakon čega slijedi razdoblje od 10 dana mirovanja.
Compounds of formula (I) 
Spoj sa formulom (I)
The process according to claim 6, wherein said compound of Formula V is prepared by reducing a compound of formula VI with a reducing agent selected from the group consisting of borohydrides to provide the compound of formula V: 
Postupak u skladu s patentnim zahtjevom 6, naznačen time što se navedeni spoj Formule V dobiva reduciranjem spoja formule VI reducensom kojeg se bira iz skupine koju čine borohidridi kako bi se dobilo spoj formule V:
The transdermal delivery device of claim 1, wherein the microspheres consist essentially of the opioid antagonist and a polymer selected from the group consisting of polyesters, polyethers, poly(orthoesters), polysaccharides, cyclodextrins, chitosans, poly (E-caprolactones), polyanhydrides, albumin, blends and copolymers thereof. 
Sredstvo za transdermalno davanje prema zahtjevu 1, naznačeno time da se mikrosfere u osnovi sastoje od opioidnog antagonista i polimera odabranog iz skupine koja se sastoji od poliestera, polietera, poli(ortoestera), polisaharida, ciklodekstrina, citosana, poli (Z-kaprolaktona), polianhidrida, albumina, njihovih mješavina i kopolimera.
The pharmaceutical composition for use according to any of claims 2, 3 or 5-14, wherein the periodic administration of glatiramer acetate is effected once every 5 to 9 days. 
Farmaceutski sastav za uporabu u skladu s bilo kojim od patentnih zahtjeva 2,3 ili 5-14, naznačen time, da so periodičko davanje glatiramer acetata provodi jednom svakih 5 do 9 dana.
Aromatic N-heterocyclic substances, particularly those containing two nitrogen atoms, are particularly preferred. 
Aromatičke N-heterocikličke tvari, naročito one koje sadržavaju dva dušikova atoma, su naročito poželjne.
The method of claim 1, wherein the initial density of said mammalian cells is at least 2×106 cells/mL. 
Postupak prema Zahtjevu 1, naznačen time, što je inicijalna gustoća spomenutih stanica sisavaca najmanje 2x10* stanica/mL,
A method according to any one of claims 1 - 7, wherein the Enteroviral particles are of an Enterovirus selected from the group consisting of polioviruses, Coxsackie A viruses, Coxsackie B viruses, Echoviruses, Rhinoviruses and Enteroviruses 68, 69, 70, 71 and 73 . 
Postupak prema bilo kojem od patentnih zahtjeva 1 - 7, naznačen time što su enterovirusne čestice iz roda Enterovirus odabrane iz grupe koja se sastoji od poliovirusa, Coxsackie A virusa, Coxsackie B virusa, echovirusa, rinovirusa i enterovirusa 68, 69, 70, 71 i 73 .
depolymerising and sizing said polysaccharide to provide an oligosaccharide; and 
(b) depolimeriziranje i smanjivanje navedenog polisaharida kako bi se osigurao oligosaharid; i
an elongated rib element extending away from the second major surface and having an elongated length and a width, and the width being less than the surface width and forming a portion of the polymeric body and formed of the first thermoplastic material; a plurality of fibers forming a fiber dispersion within the polymeric body, the fibers having an average length of less than 15 mm and an average diameter of less than 50 micrometers; 
Kompozitni strukturalni dio (10; 100; 200) prema patentnom zahtjevu 8, koji nadalje sadrži množinu vlakana koja čine vlaknastu disperziju unutar polimernog tijela (20), vlakna imaju prosječnu dužinu od manje od 15 mm i prosječni promjer od manje od 50 mikrometara, pri čemu polimerno tijelo (20) sadrži 10 % do 50 % po masi vlaknaste disperzije.
The method of 50, wherein the anti-cancer agent is selected from the group consisting of an antibody, a small molecule, an antimetabolite, an alkylating agent, a topoisomerase inhibitor, a microtubule-targeting agent, a kinase inhibitor, a protein synthesis inhibitor, an immunotherapeutic, a hormone or analog thereof, a somatostatin analog, a glucocortocoid, an aromatose inhibitor, and an mTOR inhibitor. 
(a) drugo antitijelo je anti-IGFIR antitijelo, anti-EGFR antitelo ili anti-cmet antitijelo; ili (b) sredstvo je antimetabolit, alkirajuće sredstvo, inhibitor topoizomerase, sredstvo sa ciljanim djelovanjem na mikrotubule, inhibitor kinaze, inhibitor sinteze proteina, imunoterapeutik, hormon ili njegov analog, analog somatostatina, glukokortokoid, inhibitor aromatoze, inhibitor mTOR, mala molekula koja ciljano djeluje na IGFIR ili mala molekula koja ciljano djeluje na EGFR.
wherein the term "aryl", alone or in combination, means a carbocyclic aromatic system containing one or two rings wherein such rings may be attached together in a fused manner and wherein any aryl may have 1 or more substituents independently selected from C1-C6 alkyl, hydroxyl, halo, haloalkyl, nitro, cyano, alkoxy and C1-C6 alkylamino. 
Kama A gdje izraz "aril", pojedinačno ili u kombinaciji, označava karbociklički aromatični sustav koji sadrži jedan ili dva prstena pri čemu takvi prstenovi mogu biti spojeni i gdje aril može imati 1 ili više supstituenata nezavisno izabranih od C;-Cg alkila, hidroksila, halo, haloalkila, nitro, cijano, alkoksi i C;-Cg alkilamina.
For example, different hydrophobic/hydrophilic characteristics may be imparted to the rapamycin carbohydrate derivative by manipulation of the linker. 
Na primjer, manipulacijom veznika moguće je uljikohidratnom derivatu rapamicina dodijeliti različita hidrofobna/hidrofilna svojstva.
The aqueous emulsion is filtered under vacuum and the product is extracted with ethyl acetate (2 x 150 ml). 
Vodenu emulziju se profiltrira pod vakuumom i proizvod se ekstrahira s etil acetatom (2 x 150 ml).
A compound of formula I, or formula II, wherein 
PATENTNI ZAHTJEVI 1. = Spoj formule I, ili formule II, 5
an endogenous λ (lambda) light chain allele comprising an unrearranged human lambda variable (hVλ) and an unrearranged human lambda joining (hJλ) gene segment, and a deletion of a first Vλ-Jλ-Cλ gene cluster of said endogenous mouse λ light chain allele and a replacement, in whole or in part, of the Vλ-Jλ gene segments of the second Vλ-Jλ-Cλ gene cluster of said allele with said human Vλ and Jλ gene segments which are operably linked to an intact mouse Cλ constant region gene of said second Vλ-Jλ-Cλ gene cluster, where the endogenous enhancers Enh 2.4, mouse lambda 3' enhancer (Enh) and Enh 3.1 are maintained intact in said λ light chain allele. 
Mišji embrio koji sadrži, formiran je iz ili se dobiva iz mišje embrionalne matične stanice prema zahtjevu 13, naznačen time, što se mišji embrio sastoji od alela endogenog lakog A (lambda) lanca koji sadrži nepreuređeni humani segment gena VX i nepreuređeni humani segment gena JA, pri čemu se stanica sastoji od brisanja prvog genskog klastera VA-JACA spomenutog alela endogenog mišjeg lakog A lanca i zamjene, u potpunosti ili djelomično, sa segmentima gena VA-JX drugog genskog klastera VA-JA-C2 spomenutog alela sa spomenutim humanim segmentima gena VA i JA koji su operabilno povezani s netaknutom mišjom konstantnom regijom gena CA spomenutog drugog genskog klastera VA-JACA, pri čemu su endogeni pojačivači Enh 2.4, mišji lambda 3' pojačivač (Enh) i Enh 3.1 netaknuti u spomenutom alelu lakog 2 lanca.
The process according to claim 9 wherein the solvent system in step a) is a mixture of 1-methylethyl acetate and water. 
Postupak prema zahtjevu 8 naznačen time da je sustav otapala iz koraka a) smjesa 1-metiletil acetata 1 vode.
The compound as claimed in claim 17, wherein Rc3 is C1-6 alkyl substituted by one cyano group, and Rc4 is hydrogen, or a pharmaceutically acceptable salt thereof, or a solvate thereof. 
Spoj u skladu s patentnim zahtjevom 17, naznačen time što je Rc3 C1-6 alkil, supstituiran s jednom skupinom cijano, a Rc4 je vodik, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
In a preferred embodiment, a soft chewable veterinary composition comprising an isoxazoline active agent of formula (I) is provided, wherein: 
Mekani veterinarski pripravak za žvakanje u skladu sa zahtjevom 1, naznačen time, da izoksazolin formule (I) je spoj A (engl. compound A): Per -NH Gi
The shell structure of claim 7 wherein said liner is constructed from a closed cell foam and can be washed and sterilized for reuse. 
Prenosiva udlaga za nogu u skladu s patentnim zahtjevom 7, naznačena time što je navedena podstava (23) konstruirana iz pjene zatvorenih ćelija i može se prati i sterilizirati za ponovnu upotrebu.
A B2 agonist for use according to claim 18 wherein the patient is suffering from a pre-existing heart condition or condition that would be aggravated by tachycardia. 
B2 agonist za uporabu prema zahtjevu 18 naznačen time, da pacijent pati od postojećeg stanje srca ili stanja koje će biti pogoršano tahikardijom.
reacting an intermediate of formula (II) with R2b-B(OH)2 in the presence of a suitable catalyst, a suitable solvent, and a suitable base wherein W1 represents a suitable leaving group, wherein R2b represents Het or alkyl and wherein R1, R3 to R7, p, q and X are defined as in claim 1; 
(1) R" (la-2) pri čemu W, predstavlja pogodnu odlaznu skupinu, pri čemu R* predstavlja Het ili alkil i pri čemu su R', R* do R', p, q i X kako je definirano u patentnom zahtjevu 1; reakciju intermedijera formule (IL) sa
It is also preferred for the binding molecule of the invention that first and the second domain form a molecule that is selected from the group of (scFv)2, (single domain mAb)2, scFv-single domain mAb, diabody or oligomeres thereof. 
Vezujuća molekula prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što prva i druga domena tvore molekulu koja je odabrana iz skupine koja sadrži (scFv),, (jedno domensko mAb),, scFv-jedno domensko mAb, diatijelo ili njihove oligomere.
The dried powder for use according to claim 13, wherein for administration the dried powder is reconstituted to a solution suitable for intravenous administration. 
Suhi prah za korištenje prema zahtjevu 15, naznačen time da je za primjenu suhi prah rekonstituiran u otopinu prikladnu za intravensku primjenu.
The mixture was cooled and pH adjusted to approx. 3 with NaOH. 
Smjesa se ohladi i pH podesi na otprilike 3 sa NaOH.
The system of claim 1, wherein the molecular weight of the HA is less than or about 50 kDa. The system of claim 1, wherein the HA is in an amount of about 0.1%. The system of claim 1, wherein the cosmeceutical formulation is partially saturated with oxygen. 
Formulacija prema jednom od zahtjeva 1-8, naznačena time što a) = molekularna masa HA iznosi manje ili približno 50 kDa; b) količina HA iznosi približno 0,1%; ili c) molekularna masa HA iznosi manje ili približno 50 kDa, a količina HA iznosi približno 0,1% . Formulacija prema jednom od zahtjeva 1-9, naznačena time što je formulacija djelomično zasićena, zasićena ili prezasićena kisikom.